Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17377200 | 0.89 | KDM4E (0.43) | FFAR2KDM4EALDH1A1GAACHRM2 | |
| SCHEMBL17378957 | 0.88 | KDM4E (0.47) | FFAR2KDM4EALDH1A1GAACHRM2 | |
| SCHEMBL17378959 | 0.88 | KDM4E (0.47) | FFAR2KDM4EALDH1A1GAACHRM2 | |
| SCHEMBL19743020 | 0.88 | ALDH1A1 (0.44) | FFAR2KDM4EALDH1A1GAA | |
| SCHEMBL19742975 | 0.88 | FFAR2 (0.47) | FFAR2KDM4EALDH1A1GAACHRM2 | |
| SCHEMBL17378989 | 0.87 | KDM4E (0.48) | FFAR2KDM4EALDH1A1GAACHRM2 | |
| SCHEMBL17377289 | 0.87 | FFAR2 (0.50) | FFAR2KDM4EALDH1A1GAACHRM2 | |
| SCHEMBL19743001 | 0.87 | FFAR2 (0.50) | FFAR2KDM4EALDH1A1GAAHTT | |
| SCHEMBL17377225 | 0.87 | KDM4E (0.43) | FFAR2KDM4EALDH1A1GAA | |
| SCHEMBL17378958 | 0.86 | ALDH1A1 (0.47) | FFAR2KDM4EALDH1A1GAACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369492-A1 | 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-28 | — | — | US | claimed |
| EP-3160955-A1 | 1,3-SUBSTITUTED 2-AMINOINDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY AND INFLAMMATORY BOWEL DISEASE | Takeda Pharmaceutical Company Limited (JP) | 2017-05-03 | — | — | EP | claimed |
| WO-2015198046-A1 | 1,3-SUBSTITUTED 2-AMINOINDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY AND INFLAMMATORY BOWEL DISEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-30 | — | — | WO | claimed |
| US-20170369492-A1 | 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369492-A1 | 1,3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES AND ANALOGUES USEFUL IN THE TREATMENT OR PREVENTION OF DIABETES MELLITUS, OBESITY, AND INFLAMMATORY BOWEL DISEASE | GPR119, IDO1, IDO2 | FFAR2 380/4885KDM4E 556/4885ALDH1A1 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.